Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

New Paradigm Would Open More Avenues To Obesity Drug Approval

Aug 20 2012

• By Cathy Dombrowski

Related Content

What <em>Belviq</em> Labeling Means For Other Obesity Drug Sponsors

Jul 02 2012

Antibiotics Approval Changes GAINing Acceptance; PDUFA May Not Get LPADed Out

Apr 17 2012

Panel Continues To Push For Obesity CV Guidance As It Backs <i>Contrave</i> Approval

Dec 13 2010

Orexigen On Quicker-Than-Expected Pace To Obtain Data Needed To Re-File NDA For Contrave

Aug 07 2012

REMS For <em>Qsymia</em> Limits Distribution, But Vivus To Explore Expanding Access

Jul 23 2012

<em>Qsymia</em> Sales Reps Recruited For Experience With Metabolic Products

Jul 23 2012

Takeda Bulks Up In Obesity With Orexigen Deal

Sep 02 2010

Related Companies

Arena Pharmaceuticals, Inc.

Vivus, Inc.

Orexigen Therapeutics, Inc.

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window